The in vitro effects of new D186 dendrimer on virulence factors of Candida albicans

Journal of Antibiotics

Volumn 67, Issue 6, 2014, Pages 425-432

  Staniszewska, Monika ^a   Bondaryk, Małgorzata ^a   Zielińska, Paulina ^b   Urbańczyk Lipkowska, Zofia ^b  

^a NATIONAL MEDICINES INSTITUTE   (Poland)

^b INSTITUTE OF ORGANIC CHEMISTRY   (Poland)

Author keywords

antifungal activity; Candida albicans; virulence factors

Indexed keywords

AMPHOTERICIN B; ASPARTIC PROTEINASE; D186 DENDRIMER; DENDRIMER; SAP5 PROTEIN; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CONCENTRATION RESPONSE; GENE ACTIVITY; GENE EXPRESSION; HYDROPHOBICITY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACTINS; ADHESIVENESS; ANTIFUNGAL AGENTS; ASPARTIC ACID ENDOPEPTIDASES; CACO-2 CELLS; CANDIDA ALBICANS; CELL WALL; DENDRIMERS; FUNGAL PROTEINS; GENE EXPRESSION REGULATION, FUNGAL; HUMANS; VIRULENCE FACTORS;

EID: 84903547359     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2014.25     Document Type: Article

References (52)

1. Zarb, P. et al. Antifungal therapy in European hospitals: data from the ESAC point-prevalence surveys 2008 and 2009. Clin. Microbiol. Infect. 18, E389-E395 (2012
2. Kanafani, Z. A. & Perfect, J. R. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clin. Infect. Dis. 46, 120-128 (2008 (Pubitemid 351263573)
3. Anon. Voriconazole. Med. Lett. Drugs Ther. 44, 63-65 (2002
4. Fang, B., Zhou, C. H. & Rao, X. C. Synthesis and biological activities of novel amine-derived bis-azoles as potential antibacterial and antifungal agents. Eur. J. Med. Chem. 45, 4388-4398 (2010
5. Mayer, F. L., Wilson, D. & Hube, B. Candida albicans pathogenicity mechanisms. Virulence 4, 119-128 (2013
6. Braga-Silva, L. A. & Santos, A. L. S. Aspartic protease inhibitors as potential anti-Candida albicans drugs: impacts on fungal biology, virulence and pathogenesis. Curr. Med. Chem. 18, 2401-2419 (2011
7. Calugi, C. et al. Bicyclic peptidomimetics targeting secreted aspartic protease 2 (SAP2) form Candida albicans reveal a constrained inhibitory chemotype. Bioorg. Med. Chem. 20, 7206-7213 (2012
8. Dalle, F. et al. Cellular interactions of Candida albicans with human oral epithelial cells and enterocytes. Cell Microbiol. 12, 248-271 (2010
9. Martin, R., Wächtler, B., Schaller, M., Wilson, D. & Hube, B. Host-pathogen interaction and virulence-associated genes during Candida albicans oral infections. Int. J. Med. Microbiol. 301, 417-422 (2011
10. Jackson, B. E., Wilhelmus, K. R. & Hube, B. The role of secreted aspartyl proteinases in Candida albicans keratitis. Invest. Ophthal. Vis. Sci. 48, 3559-3565 (2007 (Pubitemid 351261090)
11. Correia, A. et al. Limited role of secreted aspartyl proteinases Sap1 to Sap6 in Candida albicans virulence and host immune response in murine hematogenously disseminated candidiasis. Infect. Immun. 78, 4839-4849 (2010
12. White, T. C. & Agabian, N. Candida albicans secreted aspartyl proteinases: isoenzyme pattern is determined by cell type, and levels are determined by environmental factors. J. Bacteriol. 177, 5215-5221 (1995
13. Taylor, B. N. et al. Profile of Candida albicans-secreted aspartic proteinase elicited during vaginal infection. Infect. Immun. 73, 1828-1835 (2005 (Pubitemid 40470772)
14. Cadicamo, C. D. et al. Design, synthesis, inhibition studies, and molecular modeling of pepstatin analogues addressing different secreted aspartic proteinases of Candida albicans. Biochem. Pharmacol. 85, 881-887 (2013
15. Naglik, J. R., Moyes, D. L., Wächtler, B. & Hube, B. Candida albicans interactions with epithelial cells and mucosal immunity. Microbes Infect. 13, 963-976 (2011
16. Hube, B., Monod, M., Schofield, D. A., Brown, A. J. P. & Gow, N. A. R. Expression of seven members of the gene family encoding secretory aspartyl proteinases in Candida albicans. Mol. Microbiol. 14, 87-99 (1994 (Pubitemid 24312822)
17. Staniszewska, M. et al. In vitro study of secreted aspartyl proteinases Sap1 to Sap3 and Sap4 to Sap6 expression in Candida albicans pleomorphic forms. Pol. J. Microbiol. 61, 247-256 (2012
18. Naglik, J. R., Challacombe, S. J. & Hube, B. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol. Mol. Biol. Rev. 67, 400-428 (2003 (Pubitemid 37122527)
19. Naglik, J. R. et al. Quantitative expression of the Candida albicans secreted aspartyl proteinase gene family in human oral and vaginal candidiasis. Microbiology 154, 3266-3280 (2008
20. Lermann, U. & Morschhäuser, J. Secreted aspartic proteases are not required for invasion of reconstituted human epithelia by Candida albicans. Microbiology 154, 3281-3295 (2008
21. Braga-Silva, L. A. et al. Trailing end-point phenotype antibiotic-sensitive strains of Candida albicans produce different amounts of aspartyl peptidases. Braz. J. Med. Biol. Res. 42, 765-770 (2009
22. Bertini, A. et al. Comparison of Candida parapsislosis, Candida orthopsilosis, and Candida methapsislosis adhesive properties and pathogenicity. Int. J. Med. Microbiol. 303, 98-103 (2013
23. Lo, H. J. et al. Nonfilamentous C. albicans mutants are avirulent. Cell 90, 939-949 (1997
24. Staniszewska, M., Bondaryk, M., Siennicka, K. & Kurzatkowski, W. Ultrastructure of Candida albicans pleomorphic forms: phase-contrast microscopy, scanning and transmission electron microscopy. Pol. J. Microbiol. 61, 129-135 (2012
25. Moazeni, M. et al. RNA-mediated gene silencing in Candida albicans: inhibition of hyphae formation by use of RNAi technology. Mycopathologia 174, 177-185 (2012
26. De Bernardis, F., Mondello, F., San Milan, R., Ponton, J. & Cassone, A. Biotyping virulence properties of skin isolates of Candida parapsilosis. J. Clin. Microbiol. 37, 3481-3486 (1999 (Pubitemid 29491078)
27. Cassone, A. et al. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J. Infect. Dis. 180, 448-453 (1999 (Pubitemid 30256327)
28. Korting, H. C. et al. Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients. Antimicrob. Agents Chemother. 43, 2038-2042 (1999 (Pubitemid 29395205)
29. Borg-von Zepelin, M. et al. HIV-protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic proteases. J. Invest. Dermatol. 113, 747-751 (1999
30. Braga-Silva, L. A., Mogami, S. S., Valle, R. S., Silva-Neto, I. D. & Santos, A. L. S. Multiple effects of amprenavir against Candida albicans. FEMS Yeast Res. 10, 221-224 (2010
31. Fujimoto, Z., Fujii, Y., Kaneko, S., Kobayashi, H. & Mizuno, H. Crystal structure of aspartic proteinase from Irpex lacteus in complex with inhibitor pepstatin. J. Biol. Chem. 341, 1227-1235 (2004 (Pubitemid 39092311)
32. Binkert, C. et al. Replacement of isobutyl by trifluoromethyl in pepstatin A selectively affects inhibition of aspartic proteinases. Chembiochem. 7, 181-186 (2006 (Pubitemid 43076302)
33. Polcyn, P. et al. Novel antimicrobial peptide dendrimers with amphiphilic surface and their interactions with phospholipids-insights from mass spectrometry. Molecules 18, 7120-7144 (2013
34. Falla, T. J., Karunaratne, D. N. & Hancock, R. E. W. Mode of action of the antimicrobial peptide indolicidin. J. Biol. Chem. 271, 19298-19303 (1996 (Pubitemid 26271598)
35. Rossignol, T., Kelly, B., Dobson, C. & d'Enfert, C. Endocytosis-mediated vacuolar accumulation of the human ApoE apolipoprotein-derived ApoEdpL-W antimicrobial peptide contributes to its antifungal activity in Candida albicans. Antimicrob. Agents Chemother. 55, 4670-4681 (2011
36. Lee, D. G. et al. Design of novel peptide analogs with potent fungicidal activity, based on PMAP-23 antimicrobial peptide isolated from porcine myeloid. Biochem. Biophys. Res. Commun. 293, 231-238 (2002 (Pubitemid 34694196)
37. Gillum, A. M., Tsay, E. Y. & Kirsch, D. R. Isolation of the Candida albicans gene for orotidine-50-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol.Gen. Genet. 198, 179-182 (1984 (Pubitemid 15180998)
38. Fonzi, W. A. & Irwin, M. Y. Isogenic strain construction and gene mapping in Candida albicans. Genetics 134, 717-728 (1993 (Pubitemid 23193572)
39. Puri, S. et al. Secreted aspartic protease cleavage of Candida albicans Msb2 activates Cek1 MAPK signaling affecting biofilm formation and oropharyngeal candidiasis. PLoS ONE 7, e46020 (2012
40. Schild, L. et al. Proteolytic cleavage of covalently linked cell wall proteins by Candida albicans Sap9 and Sap10. Eukaryot. Cell 10, 98-109 (2011
41. Liu, H., Köhler, J. & Fink, G. R. Suppression of hyphal formation in Candida albicans by mutation of STE12 homolog. Science 266, 1723-1726 (1994
42. Clinical and Laboratory Standards Institute Reference Method for Broth Dilution Antifungal Susceptibility Testing Standard M27-A2. 2nd edn 1-29 Wayne (Clinical and Laboratory Standards Institute, USA, 2002
43. Garibotto, F. M. et al. New small-size peptides possessing antifungal activity. Bioorg. Med. Chem. 18, 158-167 (2010
44. Amberg, D. C., Burke, D. J. & Strathern, J. N. In Methods in Yeast Genetics (eds Amberg, D. C., Burke, D. J. & Strathern, J. N.) 127-131 (Cold Spring Harbor Laboratory Press, 2005
45. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402-428 (2001
46. Zavrel, M., Majer, O., Kuchler, K. & Rupp, S. Transcription factor Efg1 shows a haploinsufficiency phenotype in modulating the cell wall architecture and immunogenicity of Candida albicans. Eukaryot. Cell 11, 129-140 (2012
47. Ramage, G., Rajendran, R., Sherry, L. & Williams, C. Fungal biofilm resistance. Int. J. Microbiol. 2012, 528521 (2012
48. Štovíček, V., Váchová , L., Kuthan, M. & Palková , Z. General factors important for the formation of structured biofilm-like yeast colonies. Fungal Genet. Biol. 47, 1012-1022 (2010
49. Décanis, N., Tazi, N., Correia, A., Vilanova, M. & Rouabhia, M. Farnesol, a fungal quorum-sensing molecule triggers Candida albicans morphological changes by downregulating the expression of different secreted aspartyl proteinase genes. Open Microbiol. J. 5, 119-126 (2011
50. Park, C., Cho, J., Lee, J. & Lee, D. G. Membranolytic antifungal activity of arenicin-1 requires the N-terminal tryptophan and the beta-turn arginine. Biotechnol. Lett. 33, 185-189 (2011
51. Saravanan, R. et al. Design of short membrane selective antimicrobial peptides containing tryptophan and arginine residues for improved activity, salt-resistance, and biocompatibility. Biotechnol. Bioeng. 111, 37-49 (2014
52. Podorieszach, A. P. & Huttunen-Hennelly, H. E. K. The effects of tryptophan and hydrophobicity on the structure and bioactivity of novel indolicidin with promising pharmaceutical potential. Org. Biomol. Chem. 8, 1679-1687 (2010).